EVIDENCE - BASED ANTIMICROBIAL EFFICACY.

Clinical & Technical Advantages

2

Release Rate Timing

1

Surgical Practice Fit

Most bacteria are doubling every 20-30 minutes and the coating has to work on gram+ and gram- bacteria. Silver Bullet’s blend of Silver and Platinum is highly effective in killing bacteria locally and has outperformed all other antimicrobial coatings in biofilm reduction.

OrthoFuzIon™ is designed to withstand the mechanical demands of orthopedic procedures, including abrasive forces, bending, and contouring. Silver Bullet’s multi-step coating process helps maintain coating integrity and resistance to flaking and cracking while supporting application across a broad range of implant products. To date, Silver Bullet’s AntiBacterIon® coating has been evaluated in over 20 dental implant patients and demonstrated superior biofilm reduction compared to other antimicrobial coatings.

Non-Toxic Coating

3

The coating, its impurities, and any by-products must not be toxic to surrounding tissue. Silver Bullet’s AntiBacterIon™ coating has passed recommended biocompatibility testing requirements and is the only coating shown to promote new tissue formation, an important factor against implant-related infection.

Intellectual Property

4

Supported by 30+ patents, the company’s IP portfolio leads major technical claims surrounding the interlaced uniplanar sputtering of two dissimilar metals to create a targeted galvanic effect in physiologic conditions. While engineered for application across all medical fields of use, the technology primarily targets orthopedic and dental vertical markets and is reinforced by confidential, proprietary SOPs for coating and post-treatment enhancement.

Antimicrobial Efficacy vs. Key Pathogens

In vitro time-kill kinetic assays demonstrate rapid, broad-spectrum bactericidal activity within 24 hours. Silver Bullet's coating achieved significant log reductions across key Gram-positive and Gram-negative clinical pathogens compared to standard controls.

Clinical Studies and Press

  • See study HERE

    An in vivo comparison of implant materials found that silver-based coatings exhibited substantially less biofilm formation and bacterial growth than conventional titanium and zirconia materials.

  • Study is pending publication.

    To evaluate biofilm formation, 18 healthy volunteers wore test appliances featuring four new technologies and four commercial STMN controls for 24 hours. The retrieved discs were analyzed in vitro via optical density and safranin staining.

    Source: Nicola U. Zitzmann Prof. Dr. med, dent, PhD, Straumann

  • Study is pending publication.

    A clinical study of 33 patients undergoing bone-level implant placements evaluated three novel antibacterial-coated push-on cones against a TAN control group. Coatings were analyzed for biofilm formation via microbiological testing at 48 hours, 2 weeks, and 3 months, alongside clinical evaluations of plaque index, gingival index, probing pocket depth, and bleeding on probing.

    Source: Nicola U. Zitzmann Prof. Dr. med, dent, PhD, Straumann

  • Study is pending publication.

    Metagenomic analysis demonstrates that timepoint exerts a stronger influence on overall biofilm diversity than surface material. Among the tested groups, Silver Bullet (SB) emerged as the most biologically active surface, driving a distinct taxonomic shift from early colonizers to late-stage bacterial communities across the 3-month evaluation period.

    Source: Nicola U. Zitzmann Prof. Dr. med, dent, PhD, Straumann

  • Study is pending publication.

    Scanning electron microscopy (SEM) and molecular analysis demonstrate that Silver Bullet (SB) surfaces support significantly higher biomass accumulation and host cell adhesion after 2 weeks compared to control materials. Absolute quantification of RPL-P0 transcripts via ddPCR confirms SB achieved the highest density of attached host cells across all tested groups.

    Source: Nicola U. Zitzmann Prof. Dr. med, dent, PhD, Straumann

  • Watch the episode HERE

    Host Tiger Buford is joined by Paul Chirico, co-founder, President, and CEO of Silver Bullet Therapeutics, Inc. Paul shares insight into his company’s revolutionary AntiBacterlon® coating technology.

  • Read the article HERE

    Silver Bullet Therapeutics receives CE Mark approval for its antimicrobial OrthoFuzIon™ Bone Screw System, allowing the commercial sale of solid and cannulated titanium screws with AntiBacterIon™ coating across the European Union for orthopedic procedures throughout the body.

  • Read the article HERE

    Silver Bullet Therapeutics is awarded two new patents covering coatings for the controllable release of antimicrobial metal ions, further expanding its intellectual property portfolio for medical device infection prevention.

  • Read articles HERE

    FirstWord HealthTech news, press releases, and regulatory updates specifically covering Silver Bullet Therapeutics’ OrthoFuzIon™ antimicrobial bone screw system.